Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
By R. Wunderink, J. Rello, S. Cammarata, R. Croos-Dabrera, Marin Kollef. Chest, 2003
628 citations recorded by the source corpus.
Subfields: Critical Care and Intensive Care Medicine, Epidemiology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/b1ac6880e4f2e9eabff533630f19d7c84c8b46bf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Critical Care and Intensive Care Medicine
In Epidemiology
In Infectious Diseases
Citations in the corpus
- Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. (2011, neutral): “improved survival in the linezolid arm [214].”
- Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. (2008, methodology): “Linezolid is an alternative to vancomycin for the treatment of MRSA VAP and may be preferred on the basis of a subset analysis of two prospective randomized trials (Level II) (241, 276, 286).”
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007, background): “Neither linezolid [241] nor vancomycin [238] is an optimal drug for methicillin-sensitive S.”